Replimune Group (NASDAQ:REPL) Stock Price Up 8.2% – Here’s Why

Replimune Group, Inc. (NASDAQ:REPL) shares traded up 8.2% on Friday . The company traded as high as $13.03 and last traded at $12.99. 742,437 shares were traded during mid-day trading, a decline of 29% from the average session volume of 1,046,092 shares. The stock had previously closed at $12.01.

Analyst Ratings Changes

Several analysts recently commented on REPL shares. Jefferies Financial Group raised their price target on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Replimune Group in a research note on Friday, November 22nd. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. BMO Capital Markets lifted their price objective on Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Friday, November 22nd. Finally, Roth Mkm started coverage on Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $17.29.

Replimune Group Trading Up 4.8 %

The company has a fifty day simple moving average of $12.23 and a two-hundred day simple moving average of $10.64. The company has a market capitalization of $861.37 million, a P/E ratio of -4.13 and a beta of 1.26. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. On average, analysts forecast that Replimune Group, Inc. will post -2.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the transaction, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at $2,509,013.88. The trade was a 4.72 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.80% of the stock is owned by insiders.

Institutional Trading of Replimune Group

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Baker BROS. Advisors LP raised its position in shares of Replimune Group by 10.0% during the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after buying an additional 1,000,000 shares during the last quarter. Millennium Management LLC lifted its position in shares of Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after acquiring an additional 2,656,173 shares during the period. Braidwell LP grew its holdings in shares of Replimune Group by 203.0% during the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after purchasing an additional 2,057,460 shares in the last quarter. State Street Corp increased its position in shares of Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after purchasing an additional 1,182,181 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Replimune Group by 17.9% in the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after purchasing an additional 217,308 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.